Core Points - Duori Pharmaceutical announced on September 30 that it received a notification from its controlling shareholder, Tibet Jiakang Times Technology Development Co., Ltd., regarding a potential change in company control [1] - The company has applied for a trading suspension starting from September 29, 2025, with an expected duration of no more than two trading days [1] - As of the announcement date, the parties involved are actively advancing the transaction, but no formal agreement has been signed, leading to uncertainty about the resumption of trading on October 9, 2025 [1] - To ensure fair information disclosure and protect investor interests, the company has applied for an extension of the trading suspension, which is expected to last no more than three additional trading days [1]
多瑞医药：关于筹划控制权变更进展暨继续停牌的公告